Clinical Relevance of Estrogen Reactivity in the Breast Cancer Microenvironment

Purpose Estrogen signals play an important role in the phenotype of estrogen receptor-positive breast cancer. However, comprehensive analyses of the effect of responsiveness to estrogen signals on the tumor microenvironment and survival in large cohorts of primary breast cancer patients have been lacking. We aimed to test the hypothesis that estrogen reactivity affects gene expression and immune cell infiltration profiles in the tumor microenvironment and survival. Methods A total of 3,098 breast cancer cases were analyzed: 1,904 from the Molecular Taxonomy of Breast Cancer (METABRIC) cohort, 1,082 from The Cancer Genome Atlas (TCGA) cohort, and 112 from the Hokkaido University Hospital cohort. We divided the group into estrogen reactivity-high and estrogen reactivity-low groups utilizing the scores of ESTROGEN_RESPONSE_EARLY and ESTROGEN_RESPONSE_LATE in Gene Set Variation Analysis. Results Breast cancer with high estrogen reactivity was related to Myc targets, metabolism-related signaling, cell stress response, TGF-beta signaling, androgen response, and MTORC1 signaling gene sets in the tumor microenvironment. Low estrogen reactivity was related to immune-related proteins, IL2-STAT5 signaling, IL6-JAK-STAT3 signaling, KRAS signaling, cell cycle-related gene sets, and EMT. In addition, breast cancer with high levels of estrogen reactivity had low immune cytolytic activity and low levels of immunostimulatory cells. It also had low levels of stimulatory and inhibitory factors of the cancer immunity cycle. Patients with high estrogen reactivity were also associated with a better prognosis. Conclusion We demonstrated the relationship between estrogen reactivity and the profiles of immune cells and gene expression, as well as survival.

[1]  H. Yamashita,et al.  The Impact of Immunofunctional Phenotyping on the Malfunction of the Cancer Immunity Cycle in Breast Cancer , 2020, Cancers.

[2]  Wenzheng Bao,et al.  Artificial Intelligence Techniques to Computational Proteomics, Genomics, and Biological Sequence Analysis. , 2020, Current protein & peptide science.

[3]  I. Endo,et al.  Degree of Early Estrogen Response Predict Survival after Endocrine Therapy in Primary and Metastatic ER-Positive Breast Cancer , 2020, Cancers.

[4]  A. Weisz,et al.  Insights into the Role of Estrogen Receptor β in Triple-Negative Breast Cancer , 2020, Cancers.

[5]  T. Ishikawa,et al.  Lymphovascular invasion in breast cancer is associated with gene expression signatures of cell proliferation but not lymphangiogenesis or immune response , 2020, Breast Cancer Research and Treatment.

[6]  Kazuhiro Yoshida,et al.  KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival. , 2020, American journal of cancer research.

[7]  K. Takabe,et al.  Late recurrence of breast cancer is associated with pro-cancerous immune microenvironment in the primary tumor , 2019, Scientific Reports.

[8]  T. Ishikawa,et al.  APOBEC3-Mediated RNA Editing in Breast Cancer is Associated with Heightened Immune Activity and Improved Survival , 2019, International journal of molecular sciences.

[9]  K. Takabe,et al.  High expression of bone morphogenetic protein (BMP) 6 and BMP7 are associated with higher immune cell infiltration and better survival in estrogen receptor-positive breast cancer , 2019, Oncology reports.

[10]  S. Patnaik,et al.  Tumor Heterogeneity Correlates with Less Immune Response and Worse Survival in Breast Cancer Patients , 2019, Annals of Surgical Oncology.

[11]  J. Morales-Montor,et al.  Immune Tumor Microenvironment in Breast Cancer and the Participation of Estrogen and Its Receptors in Cancer Physiopathology , 2019, Front. Immunol..

[12]  Bin Liu,et al.  Dynamics of breast cancer relapse reveal late recurring ER-positive genomic subgroups , 2019, Nature.

[13]  Afshin Samali,et al.  The Unfolded Protein Response in Breast Cancer , 2018, Cancers.

[14]  Adrian V. Lee,et al.  An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics , 2018, Cell.

[15]  A. Butte,et al.  xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, bioRxiv.

[16]  B. Stanger,et al.  Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer , 2016, Clinical Cancer Research.

[17]  N. Samadi,et al.  Tumor microenvironment-mediated chemoresistance in breast cancer. , 2016, Breast.

[18]  A. Bardia,et al.  Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. , 2016, JAMA oncology.

[19]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[20]  A. Alayev,et al.  mTORC1 directly phosphorylates and activates ERα upon estrogen stimulation , 2015, Oncogene.

[21]  A. Aletras,et al.  Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells. , 2015, Matrix biology : journal of the International Society for Matrix Biology.

[22]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[23]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[24]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[25]  B. M. Mueller,et al.  Local adipocytes enable estrogen-dependent breast cancer growth , 2013, Adipocyte.

[26]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[27]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[28]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[29]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[30]  G. Gilkeson,et al.  Estrogen Receptors in Immunity and Autoimmunity , 2011, Clinical reviews in allergy & immunology.

[31]  M. Conaway,et al.  Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms , 2010, International journal of cancer.

[32]  Beatriz de la Iglesia,et al.  Clustering Rules: A Comparison of Partitioning and Hierarchical Clustering Algorithms , 2006, J. Math. Model. Algorithms.

[33]  J. Hartman,et al.  Estrogen receptor β inhibits 17β-estradiol-stimulated proliferation of the breast cancer cell line T47D , 2004 .

[34]  Barry Komm,et al.  Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. , 2003, Endocrinology.

[35]  D. Lannigan.  Estrogen receptor phosphorylation , 2003, Steroids.

[36]  D. Henley,et al.  Estrogens and cell-cycle regulation in breast cancer , 2001, Trends in Endocrinology & Metabolism.

[37]  K. Takabe,et al.  High expression of polo-like kinase 1 is associated with TP53 inactivation, DNA repair deficiency, and worse prognosis in ER positive Her2 negative breast cancer. , 2019, American journal of translational research.

[38]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .